Market Snapshot

S&P Futures
Dow Futures
NASDAQ Futures

Did Anything Hurt Enzolytics (ENZC) Stock Last Trading?

Related Topics

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

The stock of Enzolytics Inc (OTCPink: ENZC) closed down -3.01% to $0.1160 in the last trading session. A total of 13.98M shares exchanged hands during the session, with the price of Enzolytics stock ranging from $0.1140 to $0.1220. ENZC stock dropped despite the discovery of new target sites on HTLV-1 that was announced yesterday.

In what way did that discovery occur?

In addition to developing proprietary medicines to treat debilitating infectious diseases, Enzolytics is committed to commercializing its products worldwide. ITV-1 is ENZC’s patented treatment for HIV/AIDS, which uses inactivated pepsin fraction (IPF) as a suspension. Additionally, ENZC is the only company developing a proprietary technology for producing monoclonal antibodies (mAbs) for treating infectious diseases like HIV, rabies, influenza A, influenza B, tetanus, and diphtheria.

In an industry first, Enzolytics revealed yesterday that it has identified conserved, immutable sites on the HTLV-1 virus that it is targeting with monoclonal antibodies (mAbs).

  • The HTLV-1 virus is not a vaccine target, nor are there current antiviral drugs that are effective against the virus.
  • A conserved target site has now been identified using ENZC’s proprietary Artificial Intelligence (AI) methodology.
  • At the Institute for Preclinical Studies at Texas A&M University, ENZC plans to manufacture human monoclonal antibodies against these target sites.
  • A team from ENZC is attempting to identify critical sites on viruses that monoclonal antibodies will target to treat infectious viral diseases using Artificial Intelligence.
  • Multi-targeted monoclonal antibodies targeting a range of conserved sites are crucial for an effective treatment strategy according to ENZC’s experts.
  • EnZC is thus able to administer a “cocktail” of antibodies aimed at conserved and expectedly immutable targets.

How will ENZC excel in the future?

ENZC has now developed a comprehensive platform to produce numerous monoclonal antibodies targeting various pathogens. In ENZC’s platform, multiple conserved and expected to remain immutable sites on viruses are first identified and then fully human monoclonal antibodies that target those sites are produced. By using this approach, Enzolytics (ENZC) can tackle innumerable infectious diseases in humans with new and durable treatments.

Leave a Comment

Your email address will not be published. Required fields are marked *

Sign up for our FREE Newsletter and get:
Sign up for our FREE Newsletter and get:


Latest Posts